POLBF - Poolbeg Pharma and CytoReason identify very exciting influenza targets
(NewsDirect)
PoolbegPharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington andCytoReason co-founder and CEO David Harel speak to Thomas Warner fromProactive after announcing what they call a "significantbreakthrough" in their world-first influenza ArtificialIntelligence ('AI') Programme. Skillington says that thecollaboration has yielded some "very exciting influenzatargets" and that Poolbeg will now be "actively exploring themost effective way to bring them forward into development." Healso highlights Poolbeg's RSV-focused AI collaboration withCytoReason that concluded in 2022, saying that Poolbeg "is nowworking on validating those targets... and will have data before theend of the year."
Contact Details
ProactiveUK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.